These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 24879309)

  • 1. The CXCR4/CXCL12 axis in cutaneous malignancies with an emphasis on melanoma.
    Mitchell B; Mahalingam M
    Histol Histopathol; 2014 Dec; 29(12):1539-46. PubMed ID: 24879309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein expression of the chemokine receptor CXCR4 and its ligand CXCL12 in primary cutaneous melanoma--biomarkers of potential utility?
    Mitchell B; Leone D; Feller K; Menon S; Bondzie P; Yang S; Park HY; Mahalingam M
    Hum Pathol; 2014 Oct; 45(10):2094-100. PubMed ID: 25130395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic significance and impact of the CXCR4-CXCR7-CXCL12 axis in primary cutaneous melanoma.
    McConnell AT; Ellis R; Pathy B; Plummer R; Lovat PE; O'Boyle G
    Br J Dermatol; 2016 Dec; 175(6):1210-1220. PubMed ID: 27167239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is it possible to treat melanoma by intercepting the CXCR4/CXCL12 pathway?
    Motlak M; Mathews M; Al-Odat OS; Pandey MK
    Cytokine; 2024 Jul; 179():156629. PubMed ID: 38704961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation of chemokine receptor CXCR4 mRNA in primary cutaneous melanoma with established histopathologic prognosticators and the BRAF status.
    Mitchell B; Leone D; Feller JK; Bondzie P; Yang S; Park HY; Mahalingam M
    Melanoma Res; 2014 Dec; 24(6):621-5. PubMed ID: 25211166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of CXCL12/CXCR4 signaling axis in pancreatic cancer.
    Wu PF; Lu ZP; Cai BB; Tian L; Zou C; Jiang KR; Miao Y
    Chin Med J (Engl); 2013; 126(17):3371-4. PubMed ID: 24033967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCL27-CCR10 and CXCL12-CXCR4 chemokine ligand-receptor mRNA expression ratio: new predictive factors of tumor progression in cutaneous malignant melanoma.
    Monteagudo C; Ramos D; Pellín-Carcelén A; Gil R; Callaghan RC; Martín JM; Alonso V; Murgui A; Navarro L; Calabuig S; López-Guerrero JA; Jordá E; Pellín A
    Clin Exp Metastasis; 2012 Aug; 29(6):625-37. PubMed ID: 22526457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemokines in the melanoma metastasis biomarkers portrait.
    Neagu M; Constantin C; Longo C
    J Immunoassay Immunochem; 2015; 36(6):559-66. PubMed ID: 25839711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "CXCR4-CXCL12 and VEGF correlate to uveal melanoma progression".
    Franco R; Botti G; Mascolo M; Loquercio G; Liguori G; Ilardi G; Losito S; La Mura A; Calemma R; Ierano C; Bryce J; D'Alterio C; Scala S
    Front Biosci (Elite Ed); 2010 Jan; 2(1):13-21. PubMed ID: 20036848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LRRC4 inhibits human glioblastoma cells proliferation, invasion, and proMMP-2 activation by reducing SDF-1 alpha/CXCR4-mediated ERK1/2 and Akt signaling pathways.
    Wu M; Chen Q; Li D; Li X; Li X; Huang C; Tang Y; Zhou Y; Wang D; Tang K; Cao L; Shen S; Li G
    J Cell Biochem; 2008 Jan; 103(1):245-55. PubMed ID: 17549698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the CXCL12-CXCR4/CXCR7 axis in the progression and metastasis of bone sarcomas (Review).
    Liao YX; Zhou CH; Zeng H; Zuo DQ; Wang ZY; Yin F; Hua YQ; Cai ZD
    Int J Mol Med; 2013 Dec; 32(6):1239-46. PubMed ID: 24127013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression.
    Sun X; Cheng G; Hao M; Zheng J; Zhou X; Zhang J; Taichman RS; Pienta KJ; Wang J
    Cancer Metastasis Rev; 2010 Dec; 29(4):709-22. PubMed ID: 20839032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SDF-1/CXCR4 chemokine axis in uveal melanoma cell proliferation and migration.
    Bi J; Li P; Li C; He J; Wang Y; Zhang H; Fan X; Jia R; Ge S
    Tumour Biol; 2016 Mar; 37(3):4175-82. PubMed ID: 26490988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCL14 antagonizes the CXCL12-CXCR4 signaling axis.
    Hara T; Tanegashima K
    Biomol Concepts; 2014 May; 5(2):167-73. PubMed ID: 25372750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CXCL12-CXCR4 chemokine pathway: a novel axis regulates lymphangiogenesis.
    Zhuo W; Jia L; Song N; Lu XA; Ding Y; Wang X; Song X; Fu Y; Luo Y
    Clin Cancer Res; 2012 Oct; 18(19):5387-98. PubMed ID: 22932666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of the CXCR4/CXCL12 axis and its clinical implications in gastric cancer.
    Lee HJ; Jo DY
    Histol Histopathol; 2012 Sep; 27(9):1155-61. PubMed ID: 22806902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemokine receptor CXCR4: role in gastrointestinal cancer.
    Lombardi L; Tavano F; Morelli F; Latiano TP; Di Sebastiano P; Maiello E
    Crit Rev Oncol Hematol; 2013 Dec; 88(3):696-705. PubMed ID: 24120239
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.
    Zhou W; Guo S; Liu M; Burow ME; Wang G
    Curr Med Chem; 2019; 26(17):3026-3041. PubMed ID: 28875842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
    Zhou Y; Cao HB; Li WJ; Zhao L
    Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downregulation of the CXCR4/CXCL12 axis blocks the activation of the Wnt/β-catenin pathway in human colon cancer cells.
    Song ZY; Gao ZH; Chu JH; Han XZ; Qu XJ
    Biomed Pharmacother; 2015 Apr; 71():46-52. PubMed ID: 25960214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.